At a significance level of 5%, ibrutinib (inhibitor of Bruton’s tyrosine kinase) treatment resulted in a significant decrement of JMJD6 (arginine demethylase and lysine hydroxylase) and PHF6 expression (regulator of chromatin remodeling) in cell lines and a xenotransplantation model of DLBCL. The gene discussed is JMJD6; the disease is diffuse large B-cell lymphoma.